Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone for NAFLD
NCT02217345Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2017
- Primary completion
- Aug 2021
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of somatropin in non-alcoholic fatty liver disease (NAFLD), sponsored by Massachusetts General Hospital. Started Jun 2017; status: completed.
02
Drugs
somatropin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02217345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217345.